Serious Bacterial Infections Associated with Eculizumab: A Pharmacovigilance Study

  • Okusa Shohei
    Department of Neurology, Keio University School of Medicine, Japan
  • Takizawa Tsubasa
    Department of Neurology, Keio University School of Medicine, Japan
  • Imai Shungo
    Division of Drug Informatics, Keio University Faculty of Pharmacy, Japan
  • Oyama Munenori
    Department of Neurology, Keio University School of Medicine, Japan
  • Ishizuchi Kei
    Department of Neurology, Keio University School of Medicine, Japan
  • Nakahara Jin
    Department of Neurology, Keio University School of Medicine, Japan
  • Hori Satoko
    Division of Drug Informatics, Keio University Faculty of Pharmacy, Japan
  • Suzuki Shigeaki
    Department of Neurology, Keio University School of Medicine, Japan

抄録

<p>Objective Molecular-targeted agents, including eculizumab and rituximab, are considered treatment options for refractory myasthenia gravis (MG), but bacterial infections can occur as serious adverse events when using these agents. The present study elucidated the relative risks of bacterial infections associated with eculizumab and rituximab using a pharmacovigilance database. </p><p>Methods We analyzed eculizumab- and rituximab-associated adverse events reported between 2007 and 2021 in the US Food and Drug Administration Adverse Event Reporting System (FAERS) and herein report a refractory MG patient who developed streptococcal toxic shock syndrome during eculizumab treatment. </p><p>Patients We evaluated a 74-year-old Japanese woman with refractory MG who developed severe bacteremia after receiving eculizumab. </p><p>Results A total of 44,215 and 108,485 adverse events were reported with eculizumab and rituximab, respectively, from among 13,742,321 individual case safety reports in the FAERS database after data cleaning. We found a strong association between eculizumab and Neisseria infections. In contrast, we found only one case of meningococcal meningitis treated with rituximab. Both eculizumab and rituximab were weakly associated with streptococcal infections. Two cases of streptococcal toxic shock syndrome were associated with rituximab. </p><p>Conclusion Careful monitoring of serious bacterial infections associated with eculizumab treatment is warranted. </p>

収録刊行物

  • Internal Medicine

    Internal Medicine 63 (8), 1061-1066, 2024-04-15

    一般社団法人 日本内科学会

参考文献 (14)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ